Impairment in work and activities of daily life in patients with psoriasis: results of the prospective BioCAPTURE registry
Authors:
- Juul M. P. A. van Den ReekJRJuul M. P. A. van Den Reek
- Mark H. WeninkMWMark H. Wenink
- Marisol E. OteroMOMarisol E. Otero
- Paul M. OssenkoppelePOPaul M. Ossenkoppele
- Marcellus D. NjooMNMarcellus D. Njoo
- Bas PetersBPBas Peters
- Milan TjioeMTMilan Tjioe
- Else N. KopEKElse N. Kop
- John E. M. KörverJKJohn E. M. Körver
- Sharon R. P. DodemontSDSharon R. P. Dodemont
Open Access
- 23 January 2024
- journal article
- research article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 35 (1) , 2304025
Abstract
Background: Little is known about the extent of impairments in work and activities of daily life (ADL) in patients with psoriasis, and the influence of contextual factors such as disease-related characteristics and treatment. Therefore, this study aimed to assess these impairments in patients with psoriasis who started using biologicals/small molecule inhibitors.Methods: Using data from the prospective BioCAPTURE registry, we collected patient, disease, and treatment parameters, as well as work/ADL impairments at baseline, 6 and 12 months. Changes in impairment parameters and correlations between impairment and patient/disease characteristics were assessed using generalized estimating equations.Results: We included 194 patients in our analysis. After biological initiation, disease activity decreased significantly (PASI 11.2 at baseline versus 3.9 at 12 months, p < 0.001). Work-for-pay in this cohort was lower than in the Dutch general population (53% versus 67%, p = 0.01). In patients who had work-for-pay, presenteeism improved over time (5% at baseline versus 0% at 12 months, p = 0.04). Up to half of the patients reported impairments in ADL, which did not change over time. Associations between impairments and contextual factors varied, but all impairments were associated with worse mental/physical general functioning.Conclusion: Patients with psoriasis using biologicals are less likely to have work-for-pay. Treatment improves the work productivity of employed patients, but we were unable to detect changes in ADL performance.Keywords
This publication has 39 references indexed in Scilit:
- Feasibility, reliability and validity of a questionnaire on healthcare consumption and productivity loss in patients with a psychiatric disorder (TiC-P)BMC Health Services Research, 2013
- Effects of briakinumab treatment for moderate to severe psoriasis on health‐related quality of life and work productivity and activity impairment: results from a randomized phase III studyJournal of the European Academy of Dermatology and Venereology, 2013
- Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modelingPatient Preference and Adherence, 2013
- Quality of Life and Work Productivity Impairment among Psoriasis Patients: Findings from the National Psoriasis Foundation Survey Data 2003–2011PLOS ONE, 2012
- Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasisBritish Journal of Dermatology, 2007
- PRODISQ: a modular questionnaire on productivity and disease for economic evaluation studiesExpert Review of Pharmacoeconomics & Outcomes Research, 2005
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987
- Severe Psoriasis – Oral Therapy with a New RetinoidDermatology, 1978